Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Purity >98.0% (GC) Lenvatinib Mesylate Intermediate Factory

Tlhaloso e Khutšoanyane:

Lebitso la lik'hemik'hale: Methyl 4-Amino-2-Methoxybenzoate

CAS: 27492-84-8

Bohloeki: >98.0% (GC)

Ponahalo: Bosoeu ho isa ho Phofo e Ntle-Tšoeu kapa Likristale

Bohareng ba Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Lintlha tsa Sehlahisoa

Lihlahisoa tse Amanang

Li-tag tsa Sehlahisoa

Tlhaloso:

Lintho tsa Lik'hemik'hale:

Lebitso la Lik'hemik'hale Methyl 4-Amino-2-Methoxybenzoate
Litlhaloso tse tšoanang 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
Nomoro ea CAS 27492-84-8
Nomoro ea KAtse RF-PI1974
Boemo ba Setoko Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane
Foromo ea limolek'hule C9H11NO3
Boima ba Molek'hule 181.19
Botenya 1.179±0.060 g/cm3
Brand Ruifu Chemical

Litlhaloso:

Ntho Litlhaloso
Ponahalo Phofo e tšoeu ho isa ho e tšoeu kapa likristale
Mokhoa oa Bohloeki / Analysis >98.0% (GC)
Mokhoa oa Bohloeki / Analysis 97.5~102.5 (Nonaqueous Titration)
Melting Point 157.0~161.0℃
Tahlehelo ka ho Omisa <1.00%
Litšila ka Kakaretso <2.0%
Infrared Spectrum E Ikamahanya le Sebopeho
Proton NMR Spectrum E Ikamahanya le Sebopeho
Tekanyetso ea Teko Maemo a Khoebo
Tšebeliso Bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2)

Sephutheloana le Bobolokelo:

Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.

Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo

Melemo:

1

LBH:

Kopo:

Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) e ka sebelisoa e le bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib ke lithethefatsi tsa kankere ea qoqotho tse entsoeng ke Eisai Corporation ea Japane (Code: E7080), e leng ea inhibitor ea oral multi-receptor tyrosine kinase (RTK) 'me e ka thibela mosebetsi oa kinase oa vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), le VEGFR3 (FLT4).Lenvatinib e ka boela ea thibela ho kenya letsoho ha li-RTK tse ling ho pathological angiogenesis, ho hōla ha hlahala, le tsoelo-pele ea kankere ntle le mesebetsi ea bona e tloaelehileng ea lisele tse kenyeletsang fibroblast growth factor (FGF) receptors FGFR1, 2, 3, le 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, le RET.[Lipontšo]: Lenvatinib e loketse ho phekola bakuli ba mofetše oa qoqotho oa ho ipheta-pheta kapa mofuta oa metastasis, mofuta oa tsoelo-pele le mofuta o fapaneng oa iodine-refractory.Ka la 13 Hlakola, 2015, US FDA e amohetse sethethefatsi sa anticancer Lenvatinib bakeng sa kalafo ea mofets'e oa qoqotho.Lenvatinib ke inhibitor ea enzyme e nang le lipheo tse ngata, e khonang ho thibela VEGFR2 le VEGFR3 (vascular endothelial growth factor receptor).Lebitso la khoebo la Lenvatinib ke Lenvima.Ka May 20, 2015, European Medicines Agency (EMA) e amohetse Lenvatinib bakeng sa phekolo ea kankere ea qoqotho e hlaselang, e tsoetseng pele kapa ea metastatic (papillary, follicular, Hurthle type) kankere ea qoqotho (DTC).Tekong, nako ea ho phela ha bakuli ba DTC ea radioactive iodine-refractory DTC ba phekoloang ka Lenvatinib e ne e le likhoeli tse 18 ha boleng ba bakuli ba nkang placebo e le likhoeli tse 3 feela.

Ngola molaetsa wa hao mona mme o re romele wona